Inactive Instrument

Northwest Biotherapeutics, Inc Stock OTC Bulletin Board

US66737P5017

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

Oct. 30	Northwest Biotherapeutics, Inc. Enters into Commercial Loan Agreement with Streeterville Capital, LLC for USD 5,505,000	CI
Oct. 08	Northwest Biotherapeutics, Advent Bioservices And The UK National Health Service Blood And Transplant Announce Collaboration To Support DCVax®-L Production	CI

Valuation: Northwest Biotherapeutics, Inc

Market Cap	298M 266M 245M 222M 421M 27.91B 431M 2.93B 1.17B 14.94B 1.12B 1.09B 47.07B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	394M 352M 324M 294M 556M 36.92B 570M 3.87B 1.54B 19.77B 1.48B 1.45B 62.25B	EV / Sales 2026 *	-	EV / Sales 2027 *	10.9x
Free-Float	95.22%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news: Northwest Biotherapeutics, Inc

Oct. 30	Northwest Biotherapeutics, Inc. Enters into Commercial Loan Agreement with Streeterville Capital, LLC for USD 5,505,000	CI
Oct. 08	Northwest Biotherapeutics, Advent Bioservices And The UK National Health Service Blood And Transplant Announce Collaboration To Support DCVax®-L Production	CI
Aug. 14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 06	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
Jul. 08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
May. 15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
Apr. 15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Apr. 14	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
Nov. 14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 13	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
25-10-31	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
25-10-26	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI

More news

Press Releases: Northwest Biotherapeutics, Inc

Oct. 26	Northwest Biotherapeutics Announces Expansion of Its Technical Team: Company Expanding Key Operational Areas	PU
Oct. 26	Northwest Biotherapeutics Announces Expansion of Its Technical Team	PR
Oct. 08	Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production	PR
Oct. 06	Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference	PR
Aug. 14	Northwest Biotherapeutics: Q2 Earnings Snapshot	AQ

More press releases

Managers and Directors: Northwest Biotherapeutics, Inc

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	2007-05-31
Linda Powers CEO	Chief Executive Officer	71	2011-06-07
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	1999-12-31

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	1997-12-31
Linda Powers CHM	Chairman	71	2007-05-16
Navid Malik BRD	Director/Board Member	57	2012-03-31

More insiders

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+2.24%	+8.40%	+58.47%	+69.00%	68.22B
ARGENX SE	+4.66%	+8.90%	+16.93%	+85.41%	59.82B
LONZA GROUP AG	-0.60%	+1.73%	+24.32%	+94.40%	56.07B
BEONE MEDICINES AG	+2.55%	+15.52%	+30.43%	+120.17%	47.67B
IQVIA HOLDINGS INC.	+2.58%	+7.89%	+32.49%	+45.30%	45.95B
REVOLUTION MEDICINES, INC.	+4.09%	+6.37%	+228.06%	+899.75%	43.29B
CELLTRION, INC.	-0.47%	+9.38%	+27.53%	+52.40%	35.66B
GENMAB A/S	+3.80%	-1.00%	+98.16%	+66.79%	34.73B
INSMED INCORPORATED	+1.48%	+6.21%	-38.80%	+395.73%	25.47B
Average	+2.26%	+6.63%	+53.07%	+203.21%	46B
Weighted average by Cap.	+2.32%	+7.26%	+54.17%	+182.63%

	2026 *	2027 *
Net sales	-	38.93M 34.75M 31.98M 29.02M 55M 3.65B 56.37M 383M 152M 1.95B 146M 143M 6.15B
Net income	-	-
Net Debt	96.08M 85.76M 78.91M 71.62M 136M 9.01B 139M 944M 376M 4.82B 361M 353M 15.19B	125M 112M 103M 93.13M 177M 11.71B 181M 1.23B 489M 6.27B 469M 459M 19.75B

Northwest Biotherapeutics, Inc Stock OTC Bulletin Board

Stocks

US66737P5017

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc

Latest news: Northwest Biotherapeutics, Inc

Press Releases: Northwest Biotherapeutics, Inc

Managers and Directors: Northwest Biotherapeutics, Inc

Bio Therapeutic Drugs

Financials

Company Profile